Status:
COMPLETED
The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival
Lead Sponsor:
Sun Yat-sen University
Collaborating Sponsors:
The Second Affiliated Hospital of Kunming Medical University
Conditions:
Colorectal Cancer Metastatic
Mismatch Repair Deficiency
Eligibility:
All Genders
18-80 years
Brief Summary
Deficient mismatch repair (dMMR) or microsatellite instability high (MSI-H) accounts for 4-5% in metastatic colorectal cancer (mCRC). The efficacy and survival of patients with dMMR/MSI-H status recei...
Detailed Description
Colorectal cancer (CRC) is the one of most common cancer in the world. Loss of function of DNA mismatch repair (MMR) is an important mechanism of CRC development. Mutation or modification of MMR genes...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old
- Histologically confirmed Metastatic colorectal adenocarcinoma;
- Immunohistochemistry confirmed mismatch repair status or polymerase chain reaction (pCR) / next-generation sequencing (NGS) confirmed microsatellite status
- Received palliative chemotherapy and have complete information of treatment
Exclusion
- Patients have not tested for mismatch repair or microsatellite
- Patients have not received palliative chemotherapy or received palliative chemotherapy but treatment information incomplete
Key Trial Info
Start Date :
September 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 8 2020
Estimated Enrollment :
671 Patients enrolled
Trial Details
Trial ID
NCT04482608
Start Date
September 1 2019
End Date
June 8 2020
Last Update
July 27 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun yat-sen university cancer center
Guangzhou, Guangdong, China, 510060